Patient Compliance Europe - expert summit reviews latest trends and opinion
19 August 2006, NetworkPharma Ltd, Oxford, UK have published the latest in their KeywordPharma series of brand new conference reports intended for individuals working in and around the global pharmaceutical industry.
Patient Compliance Europe; in-depth report from the eyeforpharma conference, Amsterdam, 1-2 June 2006 is now available for purchase.
Patient non-compliance is an expensive and widespread problem for the pharmaceutical industry. With rates of non-compliance sometimes as high as 70 per cent, drug companies are losing around $25 billion each year simply through patients not taking their medicine. The impact on clinical outcomes, public health and healthcare costs is severe.
The Patient Compliance Europe Conference, organised by eyeforpharma and held in Amsterdam on 1-2 June 2006, explored the major issues surrounding patient compliance, showcasing research and case studies from major European pharmaceutical companies and how they are addressing the problem.
This Conference Insights review outlines the most pertinent issues from selected presentations at the event. It examines the most common reasons for patient noncompliance and looks at methods to combat them. It offers advice and guidance on how to implement a successful compliance programme, based on real market experiences.
The issue of who has ‘ownership’ of compliance is discussed: is it the responsibility of the brand manager, medical affairs or senior management? And who should play the role of educator: the doctor, the pharmacist, the nurse or the drug company?
The report finds that the overall responsibility lies with the pharmaceutical industry, which - public health aside - also stands to benefit most from an increase in compliance. Yet, despite a growing armoury of tools with which to educate patients on the value of medicine, a general apathy to tackle the issue head-on pervades the pharmaceutical industry. Despite conference rhetoric to the contrary, the industry doesn’t regard compliance as a major issue. And the smart brand manager who introduces a compliance programme will be elsewhere in the industry by the time its long-term impacts are realised.
The author, John Hosken, said: "Current estimates put non-compliance possibly as high as 50-70%. This is despite the well-known fact that poor compliance is associated with a lower quality of life, poor clinical outcomes, increased hospitalisations and higher overall healthcare costs. Clearly, compliance is actually synonymous with patient well-being."
All KeywordPharma publications can be purchased from ThePharmYard at www.ThePharmYard.com
NOTES
About the author
John Hosken has been closely involved in writing about, planning and implementing technology for the pharmaceutical industry for the past decade. After a career in financial and consultancy marketing, he joined Merck in 1997 as one of the pharmaceutical industry’s first internet strategy managers. He helped the company to get involved in using the web to market to doctors in a wide range of countries, moving to Acurian to develop its franchise in the clinical trials online recruitment market, and then held a range of pharmaceutical marketing posts in agencies. He has been writing on pharmaceutical marketing and technology topics for Pharmafocus since 2002, and recently contributed another in-depth report from an eyeforpharma conference (held in Barcelona, 14-15 March 2006) to the Conference Insights series, entitled Mobile and Wireless Sales Force Strategies (kwp007).
Written by pharmaceutical industry specialists, KeywordPharma publications are designed to be authoritative, relevant, succinct and helpful to pharmaceutical industry executives in their day-to-day work and in their longer term career development. Available to purchase individually as e-documents, they build into a specialist knowledge library for everyone working in and around the global pharmaceutical industry.
Developed and managed by NetworkPharma Ltd, ThePharmYard provides instant access to a unique database of specialist information which is particularly relevant to individuals working within the medical and pharmaceutical industries around the world. Titles from a diverse range of independent publishers are available to purchase in electronic document format for immediate access.
NetworkPharma Ltd is an independent, specialist company founded by Peter Llewellyn, to focus on novel approaches to disseminating information within the global medical and pharmaceutical industries. Peter Llewellyn previously founded and built the leading industry portal site, InPharm, which was subsequently purchased by John Wiley & Sons to manage alongside their other industry services, PharmaFile and Pharmafocus.
For more information contact:
For more information please contact us via our web site or directly contact Peter Llewellyn, Managing Director, NetworkPharma Ltd, email: peter@networkpharma.com
